ZA969709B - Targeted cytotoxic anthracycline analogs. - Google Patents

Targeted cytotoxic anthracycline analogs.

Info

Publication number
ZA969709B
ZA969709B ZA9609709A ZA969709A ZA969709B ZA 969709 B ZA969709 B ZA 969709B ZA 9609709 A ZA9609709 A ZA 9609709A ZA 969709 A ZA969709 A ZA 969709A ZA 969709 B ZA969709 B ZA 969709B
Authority
ZA
South Africa
Prior art keywords
nitrogen
halo
carbon
och2
excess
Prior art date
Application number
ZA9609709A
Other languages
English (en)
Inventor
Andrew V Prof Dr Schally
Attila A Dr Nagy
Ren-Zhi Dr Cai
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA969709(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of ZA969709B publication Critical patent/ZA969709B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9609709A 1995-11-27 1996-11-20 Targeted cytotoxic anthracycline analogs. ZA969709B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs

Publications (1)

Publication Number Publication Date
ZA969709B true ZA969709B (en) 1997-08-25

Family

ID=24247176

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9609709A ZA969709B (en) 1995-11-27 1996-11-20 Targeted cytotoxic anthracycline analogs.

Country Status (27)

Country Link
US (2) US5843903A (fr)
EP (2) EP0863917B1 (fr)
JP (2) JP3987575B2 (fr)
KR (2) KR100467899B1 (fr)
CN (2) CN1166597C (fr)
AT (2) ATE251179T1 (fr)
AU (1) AU709539B2 (fr)
BR (1) BR9611647B1 (fr)
CA (2) CA2471775C (fr)
CZ (1) CZ297297B6 (fr)
DE (2) DE69630233T2 (fr)
DK (2) DK1384710T3 (fr)
EA (1) EA001372B1 (fr)
ES (2) ES2310222T3 (fr)
HK (2) HK1017363A1 (fr)
HU (1) HU229870B1 (fr)
IL (3) IL134685A (fr)
IS (2) IS2178B (fr)
MX (1) MX9804119A (fr)
NO (2) NO324035B1 (fr)
NZ (1) NZ322054A (fr)
PL (3) PL187230B1 (fr)
PT (2) PT1384710E (fr)
SK (2) SK284392B6 (fr)
UA (1) UA67722C2 (fr)
WO (1) WO1997019954A1 (fr)
ZA (1) ZA969709B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
HUP0204199A3 (en) 1998-11-13 2005-09-28 Cyclacel Ltd Transport vectors
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
EP1235598A2 (fr) * 1999-11-12 2002-09-04 Angiotech Pharmaceuticals, Inc. Compositions et methodes destinees au traitement de maladies utilisant une therapie radioactive et des inhibiteurs du cycle cellulaire combines
DE60031793T2 (de) 1999-12-29 2007-08-23 Immunogen Inc., Cambridge Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
IL152466A0 (en) * 2000-04-26 2003-05-29 Mallinckrodt Inc RgD (Arg-Gly-Asp) COUPLED TO (NEURO) PEPTIDES
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
NZ532204A (en) 2001-09-21 2006-04-28 Univ Tulane Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
AU2003224644A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
DK1487493T3 (da) 2002-03-01 2010-05-25 Univ Tulane Konjugater af cytotoksiske midler og biologisk aktive peptider
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
EP1506786B1 (fr) * 2002-05-21 2016-11-23 Daiichi Sankyo Company, Limited Compositions medicinales contenant de la ghreline
AU2003234670B2 (en) 2002-05-24 2010-06-10 Angiotech International Ag Compositions and methods for coating medical implants
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
MXPA05003183A (es) 2002-09-26 2005-06-08 Angiotech Int Ag Evolturas perivasculares.
EP1594459B1 (fr) 2002-12-30 2010-02-17 Angiotech International Ag Liberation de medicaments a partir d'une composition polymere a gelification rapide
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
NZ576739A (en) * 2003-04-22 2011-01-28 Sod Conseils Rech Applic Peptide vectors for delivering paclitaxel
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
US20080132458A1 (en) * 2004-03-10 2008-06-05 Threshold Pharmaceuticals, Inc. Hypoxia-Activated Anti-Cancer Agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
JP5340155B2 (ja) * 2006-09-06 2013-11-13 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用
EP1900742A1 (fr) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugues des disorazoles et leurs dérives avec des molécules de liaison cellulaire, nouveaux dérives de disorazole, leurs modes de préparation et utilisation
US20100087370A1 (en) * 2007-02-14 2010-04-08 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
US8742076B2 (en) * 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
JP5647971B2 (ja) * 2008-04-11 2015-01-07 天津和美生物技▲術▼有限公司Ｔｉａｎｊｉｎ Ｈｅｍａｙ Ｂｉｏ−Ｔｅｃｈ Ｃｏ．Ｌｔｄ 高活性アントラサイクリン系抗生物質の誘導体、該誘導体の製造及び応用
EP2277884B1 (fr) * 2008-04-11 2017-08-23 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Dérivés antibiotiques d'anthracycline ayant une activité élevée, leurs procédés de fabrication et leurs utilisations
AU2009270988A1 (en) * 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
BRPI1008039A2 (pt) * 2009-02-20 2016-10-04 Ipsen Pharma Sas composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
CA2818713C (fr) 2010-12-02 2019-03-26 Nerviano Medical Sciences S.R.L. Procede pour la preparation de derives de la morpholinyle anthracycline
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
CN106573077B (zh) 2014-06-30 2019-07-30 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂
EP3045540A1 (fr) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Procédé enzymatique pour la fabrication régiosélective d'esters monoacides de N-Fmoc-doxorubicine-14-O-dicarboxyliques
CA3001712A1 (fr) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Conjugues cibles sstr, et ses particules et formulations
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
AU2019469641A1 (en) 2018-11-13 2021-07-01 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
IL106992A (en) * 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
ES2094136T3 (es) * 1989-12-19 1997-01-16 Pharmacia Spa Intermediarios quirales de 1,5-diyodo-2-metoxi o benciloxi.
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
ATE127476T1 (de) * 1990-04-06 1995-09-15 Univ Tulane Lhrh-analoge.
DK0450480T3 (da) * 1990-04-06 1995-08-14 Univ Tulane Somatostatinaloger
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
PL326865A1 (en) 1998-10-26
HK1052920A1 (en) 2003-10-03
JP2007045845A (ja) 2007-02-22
NO20051111L (no) 2005-03-01
US5843903A (en) 1998-12-01
AU709539B2 (en) 1999-09-02
NO324035B1 (no) 2007-07-30
JP4778405B2 (ja) 2011-09-21
DE69637604D1 (de) 2008-08-28
ES2310222T3 (es) 2009-01-01
CZ135798A3 (cs) 1998-10-14
HUP9903771A3 (en) 2000-07-28
CN1166597C (zh) 2004-09-15
CA2238574C (fr) 2004-10-19
CZ297297B6 (cs) 2006-11-15
CN1202903A (zh) 1998-12-23
BR9611647A (pt) 1999-02-23
IL119691A0 (en) 1997-02-18
KR19990071672A (ko) 1999-09-27
NO982252L (no) 1998-05-15
CA2238574A1 (fr) 1997-06-05
DK1384710T3 (da) 2008-11-17
JP2000502055A (ja) 2000-02-22
IS2634B (is) 2010-06-15
SK284672B6 (sk) 2005-08-04
EP0863917A1 (fr) 1998-09-16
KR20040037176A (ko) 2004-05-04
PL188786B1 (pl) 2005-04-29
JP3987575B2 (ja) 2007-10-10
HUP9903771A2 (hu) 2000-02-28
HK1017363A1 (en) 1999-11-19
IS8567A (is) 2006-11-09
EA199800492A1 (ru) 1998-12-24
ATE251179T1 (de) 2003-10-15
BR9611647B1 (pt) 2010-03-09
CN1137136C (zh) 2004-02-04
ES2205067T3 (es) 2004-05-01
IL119691A (en) 2002-02-10
PL191781B1 (pl) 2006-07-31
US6184374B1 (en) 2001-02-06
SK284392B6 (sk) 2005-03-04
KR100445754B1 (ko) 2004-12-08
NO982252D0 (no) 1998-05-15
PL187230B1 (pl) 2004-06-30
CA2471775A1 (fr) 1997-06-05
HK1052920B (zh) 2005-03-04
IS4734A (is) 1998-05-05
IL134685A0 (en) 2001-04-30
PT1384710E (pt) 2008-10-08
AU7572296A (en) 1997-06-19
DE69630233T2 (de) 2004-08-05
IS2178B (is) 2006-12-15
DE69630233D1 (de) 2003-11-06
UA67722C2 (en) 2004-07-15
PT863917E (pt) 2004-02-27
SK62898A3 (en) 1999-06-11
IL134685A (en) 2002-12-01
CN1405127A (zh) 2003-03-26
DK0863917T3 (da) 2004-01-19
HU229870B1 (en) 2014-10-28
NZ322054A (en) 1999-04-29
WO1997019954A1 (fr) 1997-06-05
EP0863917B1 (fr) 2003-10-01
CA2471775C (fr) 2008-01-29
ATE401305T1 (de) 2008-08-15
KR100467899B1 (ko) 2005-01-24
MX9804119A (es) 1998-09-30
EA001372B1 (ru) 2001-02-26
EP1384710B1 (fr) 2008-07-16
EP1384710A1 (fr) 2004-01-28

Similar Documents

Publication Publication Date Title
HK1052920A1 (en) Targeted cytotoxic anthracycline analogs.
HU9600963D0 (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
SE9301911D0 (sv) New peptide derivatives
MY113733A (en) Salts of an anti-migraine indole derivative
BR9813835A (pt) Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica
TW341565B (en) Indole derivatives processes and intermediates for their preparation and pharmaceutical compositions containing them
ES2061442T3 (es) Peptidos.
IT1283782B1 (it) Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
NZ331549A (en) Compounds useful in treating sexual dysfunction
NZ302072A (en) 1,3-diamino propyl stereomeric derivatives and organic acid and inorganic salts of their amine intermediates in the preparation of retroviral protease inhibitors
UA37311C2 (uk) Засіб для лікування статевої дисфункції і фармацевтичний препарат
MX9606494A (es) Compuestos organicos.
MY108849A (en) Novel compound
TW333533B (en) Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
MX9205408A (es) Metodo para tratar hipertension.
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
TH13531EX (th) สารต่อต้านเชื้อราชนิดไซคลิค เพพไทด์ และกรรมวิธีเตรียมสารเหล่านั้น
EP1210948A4 (fr) Medicaments destines aux maladies nerveuses
ATE221897T1 (de) Inhibitoren der blutplättchen-aggregation, die c- terminale aminosäurereste mit aminergen seitenketten enthalten
HUP9902556A2 (hu) Szinergetikus herbicid készítmény és eljárás annak alkalmazására
YU58300A (sh) Postupak za dobijanje 3-aminoalkohola